Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2012 14:21 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces 2011 Year End Financial Results Conference Call

SAN DIEGO, March 8, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that management will hold a conference call to discuss its 2011 year end financial...
March 06, 2012 10:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences CEO is Interviewed on CDTV.Net

SAN DIEGO, March 6, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI) (www.apricusbio.com) Chief Executive Officer Dr. Bassam Damaj said in an interview on CDTV.net that his company has...
February 16, 2012 10:06 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Shareholder Update With New Focus as a Commercially-Driven Specialty Pharmaceutical Company

SAN DIEGO, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) announced today a corporate update to address Company activities and expected...
February 15, 2012 12:36 ET | Source: Seelos Therapeutics, Inc.

Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive German Collaboration for Vitaros(R) for Erectile Dysfunction

SAN DIEGO, Feb. 15, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that its wholly-owned subsidiary...
February 09, 2012 09:29 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Prices $20.0 Million Public Offering of Common Stock and Warrants

SAN DIEGO, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) today announced that it has priced an underwritten public offering of 4,938,272...
February 08, 2012 16:03 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Proposed Public Offering of Common Stock and Warrants

SAN DIEGO, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) today announced that it intends to offer units consisting of shares of common stock...
February 03, 2012 09:33 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Acquisition of NitroMist(TM) Rights Outside North America

SAN DIEGO, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today the execution of a binding term sheet...
January 27, 2012 08:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrx for U.S. Co-Promotion of GRANISOL(R) (Granisetron) Oral Solution and AQUORAL(TM) Spray and Purchase of Non-U.S. Rights to GRANISOL(R)

SAN DIEGO and CALIFON, N.J., Jan. 27, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) and PediatRx, Inc. ("PediatRx")...
January 19, 2012 08:00 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Retains Argot Partners as Investor Relations Firm

SAN DIEGO, Jan. 19, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that it has retained Argot Partners, a...
January 17, 2012 10:03 ET | Source: Seelos Therapeutics, Inc.

Apricus Biosciences Announces Allowance of Israeli Patent, Expanding Its Patent Portfolio for the Topical Treatment of Premature Ejaculation

SAN DIEGO, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Israeli Patent Office...